Home › NCT05205343
Trans-Pacific Multicenter Collaborative Study of Minimally Invasive Proximal Versus Total Gastrectomy for Proximal Gastric and Gastroesophageal Junction Cancers
RecruitingObservational study
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion: 1. Able to speak and read English, Spanish, Japanese or Korean 2. Participants with a biopsy-confirmed diagnosis of non-metastatic gastric or GEJ adenocarcinoma, who are scheduled to undergo MIPG or MITG for curative-intention 3. Age ≥ 18 Exclusion: 1. Participants with known malabsorption syndromes or a lack of physical integrity of the upper gastrointestinal tract 2. Participants with known narcotic dependence, with average daily dose \> 5 mg oral morphine equivalent 3. Participants deemed unable to comply with study and/or follow-up procedures, at investigators' discretion 4. Participants who are pregnant (since are excluded from receiving standard-of-care MIPG or MITG)
About the study
To compare the symptoms of patients who have a MIPG to the symptoms of patients who have a MITG.
What is being tested
- Standard of Care (other)
- Control Group (other)
Sponsor: M.D. Anderson Cancer Center · Participants: 20 · Started: May 11, 2022
Contact the study team
- Naruhiko Ikoma, MD · Phone: (832) 729-2675
Official record on ClinicalTrials.gov — NCT05205343
Locations in the U.S.
| Texas | M D Anderson Cancer Center, Houston |
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.